Lamotrigine PreSolicitation

The Defense Logistics Agency (DLA) Troop Support Medical is planning to issue a national requirements contract for Lamotrigine ER Tablets. The procurement will cover multiple tablet strengths ranging from 25MG to 300MG, packaged in 30-count bottles. This will be an unrestricted and fully competitive acquisition utilizing a firm-fixed price, requirements-type contract with a one-year base period and four additional one-year option periods. The contract aims to establish a national supply source for Department of Defense, Bureau of Prisons, Indian Health Service, and Department of Veterans Affairs customers through DLA and VA prime vendor programs. Interested parties can submit proposals, which will be considered under FAR part 12 as a commercial item procurement. Potential vendors should contact Nancy Fernandez at (215) 737-4955 or Nancy.Fernandez@dla.mil for questions, and are advised to set up automated notifications for solicitation changes. The projected solicitation date is November 2024, though DLA reserves the right to issue the solicitation before or after this date.

The contract is classified under NAICS Category 325412 for Pharmaceutical Preparation Manufacturing and PSC Category 6505 for Drugs and Biologicals. There are no specific set-aside designations for this opportunity, meaning all sources may submit proposals. The solicitation documents will be posted on the DLA Bid Board System (DIBBS) and SAM.gov. While specific award values are not detailed in the pre-solicitation notice, the contract will cover national requirements, suggesting a potentially significant procurement volume. The contract timeline includes a one-year base period with four potential one-year extensions, providing a potential five-year total contract duration. Annual usage estimates will be provided in the Schedule of Supplies section of the forthcoming solicitation. The final response deadline is January 9, 2025, giving potential vendors ample time to prepare and submit their proposals for this comprehensive pharmaceutical supply contract.